04:09 AM EST, 01/14/2025 (MT Newswires) -- Vaxart ( VXRT ) said late Monday an independent data safety monitoring board has recommended that a phase 2b trial of its oral Covid-19 vaccine candidate continue without any modifications.

The company said the US Food and Drug Administration is reviewing the safety data from the study.

Upon favorable review, the company will enroll about 10,000 participants for the next phase of the trial, which seeks to compare the Vaxart ( VXRT ) pill with mRNA Covid-19 jabs, it said.